在CKD进展中个性化抗纤维素疗法
Charlotte Delrue1, Michele F Eisenga2, Joris R Delanghe3
1Department of Nephrology, Ghent University Hospital, 9000 Ghent, Belgium.
Journal of personalized medicine
|December 27, 2024
概括
慢性病 (CKD) 涉及纤维化. 这篇综述强调了精准医学和新的抗纤维素药物,以个性化治疗和有效打击纤维化.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 遗传学 遗传学 是一个
背景情况:
- 慢性病 (CKD) 标志着纤维化和细胞外基质的积累,可能导致末期病.
- 关键通路如TGF-β,Wnt/β-catenin,Notch和NF-κB都与纤维化进展有关.
- 目前的治疗方法,如氨酸- ангиотензин- 阿尔多素系统抑制剂,只会延迟CKD的进展,而不会逆转纤维化.
研究的目的:
- 审查抗纤维素药物在治疗慢性病中的关键作用.
- 强调精准医学在个性化CKD治疗策略方面的潜力.
- 讨论脏纤维化的新兴治疗点和药物.
主要方法:
- 文献综述侧重于分子通路,精准医学方法和CKD抗纤维药物开发.
- 分析蛋白质组特征 (例如CKD273) 和基因标记 (例如APOL1,COL4A5) 用于患者分层.
- 检查前临床和临床数据的抗纤维素药物,如宁泰达尼布,皮尔费尼,和针对CTGF和galectin-3的试验药物.
主要成果:
- 精准医学,整合蛋白质组,代谢组和遗传数据,为量身定制的CKD疗法提供了一条途径.
- 蛋白质和遗传标记有助于识别针对性治疗的患者亚组.
- 丁丁达尼布和皮尔费尼在脏疾病的临床前模型中表现出抗纤维素作用.
结论:
- 显著需要抗纤维素疗法来阻止或逆转CKD中的纤维化.
- 个性化治疗方法利用精准医学对有效的CKD管理至关重要.
- 针对特定纤维化机制的研究药物显示出未来CKD治疗的前景.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
299
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
299
01:22Heart Failure Drugs: Diuretics
273
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
273
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
89
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
89
01:11Renal Failure: Dose Adjustments
34
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
34
01:33Hormonal Regulation
32.7K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.7K
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
394
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
394